JP Morgan Maintains Overweight on Olema Pharmaceuticals, Lowers Price Target to $46

Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc.

OLMA

0.00

JP Morgan analyst Anupam Rama maintains Olema Pharmaceuticals (NASDAQ: OLMA) with a Overweight and lowers the price target from $52 to $46.